Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Gains from Sales and Divestitures (2021 - 2025)

BioAtla (BCAB) has 5 years of Gains from Sales and Divestitures data on record, last reported at $644995.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 551.36% year-over-year to $644995.0; the TTM value through Sep 2025 reached $644995.0, up 551.36%, while the annual FY2024 figure was $99104.0, 118.82% up from the prior year.
  • Gains from Sales and Divestitures reached $644995.0 in Q3 2025 per BCAB's latest filing, up from $561482.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $944991.0 in Q4 2021 and bottomed at $18807.0 in Q2 2023.
  • Average Gains from Sales and Divestitures over 5 years is $274645.9, with a median of $181407.0 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 91.62% in 2023, then skyrocketed 880.79% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $944991.0 in 2021, then crashed by 52.78% to $446260.0 in 2022, then plummeted by 89.85% to $45290.0 in 2023, then soared by 118.82% to $99104.0 in 2024, then skyrocketed by 550.83% to $644995.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $644995.0 in Q3 2025, $561482.0 in Q2 2025, and $363500.0 in Q1 2025.